Bausch + Lomb has halted a program related to glaucoma eye drops after a trial failure. This development has affected the company's stock, which has dropped after hours. The reason for the halt and its overall impact on the company are not entirely clear, with reports suggesting both a strengthening and a weakening of the company's position.